Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PD-L1 thresholds predict efficacy of immune checkpoint inhibition in first-line treatment of advanced gastroesophageal adenocarcinoma. A systematic review and meta-analysis of seven phase III randomized trials.
Formica V, Morelli C, Fornaro L, Riondino S, Rofei M, Fontana E, Smyth EC, Roselli M, Arkenau HT. Formica V, et al. Among authors: arkenau ht. ESMO Open. 2024 Nov;9(11):103967. doi: 10.1016/j.esmoop.2024.103967. Epub 2024 Nov 13. ESMO Open. 2024. PMID: 39541621 Free PMC article. Review.
Association between incretin-based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: A large population-based matched cohort study.
Krishnan A, Schneider CV, Arkenau HT, Mauro EM, Forner A, Scott Butsch W, Walsh D, Alqahtani SA. Krishnan A, et al. Among authors: arkenau ht. J Clin Transl Endocrinol. 2024 Sep 18;38:100370. doi: 10.1016/j.jcte.2024.100370. eCollection 2024 Dec. J Clin Transl Endocrinol. 2024. PMID: 39386155 Free PMC article.
Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors.
Bashir B, Wang JS, Falchook G, Fontana E, Arkenau HT, Carter L, Galot R, Basu B, Greystoke A, Subbiah V, Richardson DL, Orr H, Bennett G, Sharma R, Xu H, Paganoni P, Xu C, Campbell C, McKean M. Bashir B, et al. Among authors: arkenau ht. J Clin Oncol. 2024 Oct 10;42(29):3443-3452. doi: 10.1200/JCO.23.01107. Epub 2024 Sep 4. J Clin Oncol. 2024. PMID: 39231383 Clinical Trial.
Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors.
Stradella A, Johnson M, Goel S, Park H, Lakhani N, Arkenau HT, Galsky MD, Calvo E, Baz V, Moreno V, Saavedra O, Luen SJ, Mu S, Wan Q, Chang V, Zhang W, Barve M. Stradella A, et al. Among authors: arkenau ht. Cancer Med. 2024 Jul;13(13):e7385. doi: 10.1002/cam4.7385. Cancer Med. 2024. PMID: 38970256 Free PMC article. Clinical Trial.
Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors.
Mokbel S, Baciarello G, Lavaud P, Omlin A, Calabrò F, Cathomas R, Aeppli S, Parent P, Giannatempo P, Koster KL, Appel N, Gonnet P, Angius G, Tsantoulis P, Arkenau HT, Cattrini C, Messina C, Zeghondy J, Morelli C, Loriot Y, Formica V, Patrikidou A. Mokbel S, et al. Among authors: arkenau ht. Cancers (Basel). 2024 Apr 11;16(8):1465. doi: 10.3390/cancers16081465. Cancers (Basel). 2024. PMID: 38672547 Free PMC article.
First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study.
Wheatley DA, Berardi R, Climent Duran MA, Tomiak A, Greystoke AP, Joshua AM, Arkenau HT, Géczi L, Corbacho JG, Paz-Ares LG, Hussain SA, Petruželka L, Delmonte A, Chappey C, Masters JC, Michelon E, Murphy DA, Mwewa S, Cesari R, Doger de Spéville B. Wheatley DA, et al. Among authors: arkenau ht. Cancer Res Commun. 2024 Jun 28;4(6):1609-1619. doi: 10.1158/2767-9764.CRC-23-0459. Cancer Res Commun. 2024. PMID: 38669053 Free PMC article. Clinical Trial.
Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours.
Patel MR, Johnson M, Winer I, Arkenau HT, Cook N, Samouëlian V, Aljumaily R, Kitano S, Duffy C, Ge M, Elgadi M, Siu LL. Patel MR, et al. Among authors: arkenau ht. Cancer Immunol Immunother. 2024 Mar 30;73(5):89. doi: 10.1007/s00262-024-03654-0. Cancer Immunol Immunother. 2024. PMID: 38554156 Free PMC article. Clinical Trial.
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study.
Oh DY, Maqueda MA, Quinn DI, O'Dwyer PJ, Chau I, Kim SY, Duran I, Castellano D, Berlin J, Mellado B, Williamson SK, Lee KW, Marti F, Mathew P, Saif MW, Wang D, Chong E, Hilger-Rolfe J, Dean JP, Arkenau HT. Oh DY, et al. Among authors: arkenau ht. BMC Cancer. 2023 Nov 3;23(1):1056. doi: 10.1186/s12885-023-11539-1. BMC Cancer. 2023. PMID: 37919668 Free PMC article. Clinical Trial.
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial.
André T, Berton D, Curigliano G, Sabatier R, Tinker AV, Oaknin A, Ellard S, de Braud F, Arkenau HT, Trigo J, Gravina A, Kristeleit R, Moreno V, Abdeddaim C, Vano YA, Samouëlian V, Miller R, Boni V, Torres AA, Gilbert L, Brown J, Dewal N, Dabrowski C, Antony G, Zografos E, Veneris J, Banerjee S. André T, et al. Among authors: arkenau ht. JAMA Netw Open. 2023 Nov 1;6(11):e2341165. doi: 10.1001/jamanetworkopen.2023.41165. JAMA Netw Open. 2023. PMID: 37917058 Free PMC article. Clinical Trial.
167 results